Cancer immunotherapy: challenges and clinical applications
Author:
Funder
Natural Science Foundation of China
Publisher
BMJ
Subject
Genetics (clinical),Genetics
Reference32 articles.
1. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
2. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
3. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
4. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
5. Coinhibitory Pathways in Immunotherapy for Cancer
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening;Biosensors and Bioelectronics;2023-11
2. A Pan-cancer Analysis Reveals the Tissue Specificity and Prognostic Impact of Angiogenesis-associated Genes in Human Cancers;Current Bioinformatics;2023-10
3. Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review;Saudi Pharmaceutical Journal;2023-02
4. Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism;Molecules;2023-01-15
5. A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy;Nanoscale;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3